Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Tongue pigmentation Vulvovaginal candidiasis Xerostomia (3.5%) Hair Hair – alopecia (1%) Other Abdominal pain (2%) (2004): Siniscalchi A, Clin Ter 155(1), 25 (2000): Pongratz D+, JNeurolSci180(1), 82 (2.5%) Candidiasis Chills Hypersensitivity (2006): Sorenson EJ, Neurology 67(12), 2260 Injection-site reactions (sic) Phlebitis (1%) RIMANTADINE Trade names: Flumadine (Forest); Ruflual Indications: Various infections caused by influenza virus Category: Adamantane; Antiviral Half-life: 25–30 hours Reactions Skin Edema (pedal) (1–10%) Rash (sic) (1%) (1989): Hayden FG+, NEnglJMed321, 1696 (1%) Mucosal Stomatitis Xerostomia (1.6%) RIMONABANT* Synonym: SR 141716 Trade name: Acomplia (Sanofi-Aventis) Indications: Obesity Category: CB1 Cannabinoid receptor antagonist Half-life: N/A Clinically important, potentially hazardous interactions with: clarithromycin, itraconazole, ketoconazole, nefazodone, ritonavir, telithromycin Reactions Skin Diaphoresis Pruritus Eyes Visual hallucinations Other Myalgia/Myositis/Myopathy/Myotoxicity Tendinopathy/Tendon rupture Upper respiratory infection *Note: Not approved in the USA RISEDRONATE Trade name: Actonel (Procter & Gamble) Indications: Paget’s disease of bone, postmenopausal osteoporosis Category: Bisphosphonate Half-life: terminal: 220 hours Reactions Skin Edema Facial edema (2005): Barrera BA+, Osteoporos Int 16(12), 1989 (6 cases) Peripheral edema (8.2%) Pruritus (3.0%) Rash (sic) (11.5%) Stevens–Johnson syndrome (2005): Barrera BA+, Osteoporos Int 16(12), 1989 (1 case) Urticaria (2002): Gordon MS+, Endocr Pract 8(3), 202 Mucosal Glossitis (
482 RISPERIDONE Exfoliative dermatitis (0.1–1%) Furunculosis (
- Page 506 and 507: (1995): Magro CM+, JAmAcadDermatol3
- Page 508 and 509: (1993): Leenutaphong V+, Int J Derm
- Page 510 and 511: PHENYLEPHRINE Trade names: Dionephr
- Page 512 and 513: (1991): Kleier RS, Arch Dermatol 12
- Page 514 and 515: Lymphoproliferative disease (1992):
- Page 516 and 517: (2006): Andersen KE+, Contact Derma
- Page 518 and 519: Oral candidiasis Stomatodynia Vagin
- Page 520 and 521: Reactions Skin Exanthems Petechiae
- Page 522 and 523: Reactions Skin Acne (1-10%) Angioed
- Page 524 and 525: Pruritus (
- Page 526 and 527: PREDNISONE Trade names: Deltasone (
- Page 528 and 529: Other Anticonvulsant hypersensitivi
- Page 530 and 531: Xerosis Mucosal Lip ulceration (198
- Page 532 and 533: (1982): Gall H+, Derm Beruf Umwelt
- Page 534 and 535: (2006): Barkin RL+, Am J Ther 13(6)
- Page 536 and 537: PROTAMINE SULFATE Indications: Hepa
- Page 538 and 539: (1987): Shelley WB+, JAmAcadDermato
- Page 540 and 541: Hypersensitivity Myalgia/Myositis/M
- Page 542 and 543: (1999): Drayton G, Los Angeles, CA
- Page 544 and 545: (1986): Bigby M+, JAMA 256, 3358 (1
- Page 546 and 547: Nails Nails - photo-onycholysis (19
- Page 548 and 549: Hair Hair - alopecia (1-10%) Other
- Page 550 and 551: RASBURICASE Trade names: Elitek (Sa
- Page 552 and 553: RETEPLASE Synonyms: recombinant pla
- Page 554 and 555: Other Inappropriate secretion of an
- Page 558 and 559: Reactions Skin Acne (
- Page 560 and 561: RIZATRIPTAN Synonym: MK462 Trade na
- Page 562 and 563: Glossitis (1%) Stomatitis (
- Page 564 and 565: (1995): Brandstatter G+, Clin Ther
- Page 566 and 567: Mucosal Cheilitis (
- Page 568 and 569: SELENIUM Trade names: Bio-Active Se
- Page 570 and 571: Mucosal Aphthous stomatitis (
- Page 572 and 573: (2004): Vasconcelos OM+, Muscle Ner
- Page 574 and 575: (2005): Mahe E+, Transplantation 79
- Page 576 and 577: SOLIFENACIN Trade name: Vesicare (G
- Page 578 and 579: Urticaria (
- Page 580 and 581: Pruritus (1997): Golsch S+, Hautarz
- Page 582 and 583: Glossitis (2%) Oral mucosal eruptio
- Page 584 and 585: Reactions Skin Allergic reactions (
- Page 586 and 587: (1995): Hertl M+, Br J Dermatol 132
- Page 588 and 589: (1992): Bodokh I+, Presse Med (Fren
- Page 590 and 591: SULFISOXAZOLE* Trade names: Isoxazi
- Page 592 and 593: (1984): Stern RS+, JAMA 252, 1433 J
- Page 594 and 595: TACROLIMUS Synonym: FK506 Trade nam
- Page 596 and 597: (2005): Fumal I+, Dermatology 210(3
- Page 598 and 599: (2000): Ernst E+, Forsch Komplement
- Page 600 and 601: Reactions Skin Allergic reactions (
- Page 602 and 603: Reactions Skin Diaphoresis (>1%) Ed
- Page 604 and 605: Mucosal Oral ulceration (1987): Hig
Tongue pigmentation<br />
Vulvovaginal c<strong>and</strong>idiasis<br />
Xerostomia (3.5%)<br />
Hair<br />
Hair – alopecia (1%)<br />
Other<br />
Abdominal pain (2%)<br />
(2004): Siniscalchi A, Clin Ter 155(1), 25<br />
(2000): Pongratz D+, JNeurolSci180(1), 82 (2.5%)<br />
C<strong>and</strong>idiasis<br />
Chills<br />
Hypersensitivity<br />
(2006): Sorenson EJ, Neurology 67(12), 2260<br />
Injection-site reactions (sic)<br />
Phlebitis (1%)<br />
RIMANTADINE<br />
Trade names: Flumadine (Forest); Ruflual<br />
Indications: Various infections caused by influenza virus<br />
Category: Adamantane; Antiviral<br />
Half-life: 25–30 hours<br />
Reactions<br />
Skin<br />
Edema (pedal) (1–10%)<br />
Rash (sic) (1%)<br />
(1989): Hayden FG+, NEnglJMed321, 1696 (1%)<br />
Mucosal<br />
Stomatitis<br />
Xerostomia (1.6%)<br />
RIMONABANT*<br />
Synonym: SR 141716<br />
Trade name: Acomplia (Sanofi-Aventis)<br />
Indications: Obesity<br />
Category: CB1 Cannabinoid receptor antagonist<br />
Half-life: N/A<br />
Clinically important, potentially hazardous interactions<br />
with: clarithromycin, itraconazole, ketoconazole, nefazodone,<br />
ritonavir, telithromycin<br />
Reactions<br />
Skin<br />
Diaphoresis<br />
Pruritus<br />
Eyes<br />
Visual hallucinations<br />
Other<br />
Myalgia/Myositis/Myopathy/Myotoxicity<br />
Tendinopathy/Tendon rupture<br />
Upper respiratory infection<br />
*Note: Not approved in the USA<br />
RISEDRONATE<br />
Trade name: Actonel (Procter & Gamble)<br />
Indications: Paget’s disease of bone, postmenopausal<br />
osteoporosis<br />
Category: Bisphosphonate<br />
Half-life: terminal: 220 hours<br />
Reactions<br />
Skin<br />
Edema<br />
Facial edema<br />
(2005): Barrera BA+, Osteoporos Int 16(12), 1989 (6 cases)<br />
Peripheral edema (8.2%)<br />
Pruritus (3.0%)<br />
Rash (sic) (11.5%)<br />
Stevens–Johnson syndrome<br />
(2005): Barrera BA+, Osteoporos Int 16(12), 1989 (1 case)<br />
Urticaria<br />
(2002): Gordon MS+, Endocr Pract 8(3), 202<br />
Mucosal<br />
Glossitis (
Change language